2. Signaling Pathways
  3. GPCR/G Protein
  4. Prostaglandin Receptor

Prostaglandin Receptor

Prostaglandin Receptor

Related Products

PDF 2.76 MB

Prostaglandin receptor, a sub-family of cell surface seven-transmembrane receptors, are the G-protein-coupled receptors. There are currently ten known prostaglandin receptors on various cell types. Prostaglandins bind to a subfamily of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are named: DP1-2-DP1, DP2 receptors, EP1-4-EP1, EP2, EP3, EP4 receptors, FP-FP, IP1-2-IP1, IP2 receptors, TP-TP receptor. The prostaglandins are a group of hormone-like lipid compounds that are derived enzymatically from fatty acids and have important functions in the animalbody. There are currently ten known prostaglandin receptors on various cell types.

Prostaglandin Receptor Isoform Specific Products:

Prostaglandin Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-128932
    Cefminox sodium
    		Agonist 99.83%
    Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model.
    Cefminox sodium
  • HY-106067A
    Dazoxiben hydrochloride
    		Inhibitor 99.90%
    Dazoxiben hydrochloride is a potent and orally active thromboxane (TX) synthase inhibitor.
    Dazoxiben hydrochloride
  • HY-19360
    Sulprostone
    		Agonist ≥99.0%
    Sulprostone (SHB 286) is a potent and selective EP3 receptor agonist. Sulprostone (SHB 286) is a prostaglandin E2 (PGE2) analogue and has antiulcer and nonsteroidal abortifacient effects. Sulprostone has potential for the research of pregnancy termination and hemorrhages during delivery.
    Sulprostone
  • HY-118609
    EP4 receptor agonist 2
    		Agonist 99.0%
    EP4 receptor agonist 2 (compound 31) a potent EP4 receptor agonist with an EC50 value of 0.8 nM; Ki values of >100000, 38000, 3.1 nM for EP2, EP3, EP4 respectively.
    EP4 receptor agonist 2
  • HY-19998
    Taprenepag isopropyl
    		Agonist 99.02%
    Taprenepag isopropyl is a highly selective EP2 receptor agonist.
    Taprenepag isopropyl
  • HY-N1401
    20(R)-Ginsenoside Rh2
    		Inhibitor 99.84%
    20(R)-Ginsenoside Rh2 is an orally active protopanaxadiol-type saponin with multiple biological activities. 20(R)-Ginsenoside Rh2 exerts a significant inhibitory effect on non-small cell lung cancer and liver cancer by inducing cell cycle arrest and promoting apoptosis. 20(R)-Ginsenoside Rh2 exerts anti-γ-herpesvirus effects by inhibiting viral DNA replication. 20(R)-Ginsenoside Rh2 inhibits inflammatory mediators by reducing the levels of NO, PGE2, and ROS; it can delay skin photoaging by reducing ROS and inhibiting MMP-9/2 activity. 20(R)-Ginsenoside Rh2 accelerates the recovery after muscle injury by activating the Akt1/PKB signaling pathway. 20(R)-Ginsenoside Rh2 can inhibit osteoclast formation and exert an anti-osteoporosis effect.
    20(R)-Ginsenoside Rh2
  • HY-111271
    L 888607
    		Agonist 99.87%
    L 888607 is a potent, selective, stable and orally active CRTH2 agonist. L 888607 has high affinity for the human CRTH2 receptor with a Ki value of 4 nM. L 888607 can be used for the research of several physiological events and metabolite.
    L 888607
  • HY-105005
    Crisdesalazine
    		Control 98.92%
    Crisdesalazine (AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Crisdesalazine acts as a potent free radical scavenger that directly neutralizes reactive oxygen species (ROS) including hydrogen peroxide, exerting neuroprotective effects against apoptosis and axonal damage. Crisdesalazine inhibits PGE2 production, mediates inflammatory responses, and promotes the conversion of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Crisdesalazine is applicable to neuroprotection research in multiple sclerosis and spinal cord injury.
    Crisdesalazine
  • HY-118830
    13,14-Dihydro-15-keto prostaglandin D2
    		Agonist 99.90%
    13, 14-Dihydro-15-keto prostaglandin D2 (DK-PGD2) is a PGD2 metabolite formed by the 15-hydroxyl PGDH pathway. 13, 14-Dihydro-15-keto prostaglandin D2 is a selective agonist for the DP2 receptor. 13, 14-Dihydro-15-keto prostaglandin D2 can inhibit ion flux in canine colonic mucosa preparation.
    13,14-Dihydro-15-keto prostaglandin D2
  • HY-105218A
    Ifetroban sodium
    		Antagonist 99.83%
    Ifetroban (BMS-180291) sodium is an orally active antagonist of thromboxane A2 (TXA2) or prostaglandin H2 (PGH2) receptor. Ifetroban sodium shows antiplatelet activity, and inhibits tumor cell migration without affecting cell proliferation. Ifetroban sodium can be used for myocardial ischemia, hypertension, stroke, thrombosis, cardiomyopathy research.
    Ifetroban sodium
  • HY-112284
    Ebopiprant
    		Antagonist 98.65%
    Ebopiprant (OBE022) is an oral and selective prostaglandin F2α (PGF2α) receptor antagonist, with Kis of 1 nM, 26 nM for human and rat FP receptors, respectively.
    Ebopiprant
  • HY-147226
    EP3 antagonist 3
    		Antagonist 99.52%
    EP3 antagonist 3 (compound 2) is an orally active, potent and selective EP3 antagonist, with a pKi of 8.3. EP3 antagonist 3 shows excellent pharmacokinetic properties. EP3 antagonist 3 can be used for overactive bladder (OAB) research.
    EP3 antagonist 3
  • HY-136895
    AZ12672857
    		Inhibitor 98.01%
    AZ12672857 is an orally active inhibitor of EphB4 (IC50=1.3 nM) and Src kinases. AZ12672857 shows good inhibition of proliferation of c-Src transfected 3T3 cells (IC50=2 nM) as well as autophosphorylation of EphB4 in transfected CHO-K1 cells (IC50=9 nM).
    AZ12672857
  • HY-B0601
    Tafluprost acid
    		Agonist 99.80%
    Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma.
    Tafluprost acid
  • HY-50848
    BW A868C
    		Antagonist 99.90%
    BW A868C, a hydantoin compound, is a BW245C structural analogue. BW A868C is a selective and potent competitive prostaglandin D2 (PGD2) antagonist. BW A868C has no effect on other prostaglandin receptors (IP, EP1, EP2, TP and FP).
    BW A868C
  • HY-19361
    L-826266
    		Antagonist 99.70%
    L-826266 is a selective and competitive EP3 receptor antagonist. L-826266 can be used for convulsive disorders research.
    L-826266
  • HY-N0677
    Dehydroandrographolide succinate
    		Inhibitor 99.88%
    Dehydroandrographolide succinate can be extracted from herbal medicine Andrographis paniculata (Burm f) Nees, is widely used in research for viral pneumonia and viral upper respiratory tract infections because of its immunostimulatory, anti-infective and anti-inflammatory effect. Dehydroandrographolide succinate exerts antithrombotic effect. Dehydroandrographolide succinate significantly inhibits the platelet aggregation rate (ED50 = 386.9 mg/kg) by decreasing TXB2 levels. Dehydroandrographolide succinate mitigates muscle astrophy via the Akt/GSK3β and MuRF-1 pathways.
    Dehydroandrographolide succinate
  • HY-176293
    EP2 receptor antagonist-3
    		Antagonist 99.08%
    EP2 receptor antagonist-3 is a selective EP2 receptor antagonist (IC50: 8 nM in hEP2 SPA assay, 50 nM in hEP2 cAMP assay). EP2 receptor antagonist-3 increases the macrophage-mediated clearance of Amyloid-β plaques. EP2 receptor antagonist-3 can be used for the study of alzheimer’s diseases.
    EP2 receptor antagonist-3
  • HY-135259
    CAY10580
    		Agonist
    CAY10580 is a potent and selective prostaglandin EP4 receptor agonist (Ki=35 nM).
    CAY10580
  • HY-128039
    17-Phenyl-ω-trinor-PGE2
    		Agonist 99.9%
    17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production.
    17-Phenyl-ω-trinor-PGE2
Cat. No. Product Name / Synonyms Application Reactivity
Prostaglandin Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.